Background: The most common cause of activated protein C (aPC) resistance is a missense substitution (Arg506Gln), known as Factor V Leiden (FVL). Due to its low cost, many laboratories use the aPC ratio as a primary test with a unisex cut-off. However, the association between the aPC ratio and FVL including any relation to gender has been sparsely investigated. Methods: Results of the aPC ratio and FVL analyses from 1081 patients referred to the Thrombophilia Clinic at Odense University Hospital were compared. Results: In 153 FVL positive patients, the mean aPC ratio was 2.1 ± 0.3, which differed from 2.7 ± 0.4 in FVL negative individuals (p < 0.01). The receiver operating characteristics (ROC), with area under the curve (AUC) of 0.93, indicated the optimal aPC cut-off at 2.3-2.4, with sensitivity 89%-94%, specificity 71%-84%, positive predictive value 35%-48% and negative predictive value 98%-99%. In FVL positive females, the mean aPC ratio was 2.0 ± 0.3, which differed from males (2.1 ± 0.3, p < 0.05). In FVL negative females, the mean aPC ratio was 2.6 ± 0.4, also different from males (2.8 ± 0.5, p < 0.01). Of note, 35% of FVL negative females had an aPC ratio ≤2.4 against 18% in males (p < 0.01). Conclusions: Our results indicate that the aPC ratio is lower in females than in males. Due to a high negative predictive value the aPC ratio can be used as a first line test for FVL, but those found positive must be confirmed with a DNA test.
Introduction
In the coagulation cascade, the activated form of protein C (aPC) cleaves coagulation factor Va and VIIIa, thereby regulating thrombin production [1] . In some individuals, the cleaving activity of aPC is impaired, leading to prolonged factor Va and VIIIa activity. This phenomenon is termed aPC resistance and is in general depicted by an aPC ratio, measured as the ratio between plasma activated partial thromboplastin time (APTT) with and without aPC. Of note, the diagnostic cut-off values for aPC resistance depends on the method and laboratory technique, but the two major used values are ≤2.0 and ≤2. 4 . aPC resistance is considered a risk factor for venous thrombosis due to the overproduction of thrombin and consequently of fibrin [2, 3] . By far the most common cause of aPC resistance (up to 95%) is a missense mutation in chromosome 1, position 1691, with a substitution of guanine to adenine, resulting in a change of arginine to glutamine at the cleavage site of protein C [4, 5] . This mutation is known as Factor V Leiden (FVL) or Arg506Gln [3, 5] . Some laboratories investigate aPC resistance by screening for the single nucleotide polymorphism (SNP) causing the FVL mutation (Arg506Gln). This is generally considered more reliable than measuring the aPC ratio, but it is a cumbersome, more expensive approach and it also misdiagnoses the 5% with aPC resistance not having a FVL mutation, among those patients with other, more esoteric FV mutations. Therefore, many laboratories still perform the aPC ratio test due to the low-cost price, and if positive it can be confirmed by the SNP analysis for Arg506Gln. There are, however, uncertainties in this approach regarding possible differences between gender, perhaps ethnicity or more test-related matters [6] . The purpose of this study was to validate the association between aPC ratio and FVL positivity by assessing the sensitivity, specificity, positive and negative predictive values at different aPC ratios and additionally to investigate differences in these related to gender.
Materials and methods

Individuals
The present retrospective study included all patients referred for thrombophilia testing at Odense University Hospital, Denmark, between February 2013 and December 2016. After assessment by a medical doctor at the University Hospital, blood sampling was performed and samples were handled by healthcare professionals with coagulation laboratory skills.
Data extraction
Data were obtained from the regional laboratory information system BCC (CGI, Copenhagen, Denmark) for the period February 2013 to December 2016. All Danish citizens carry a unique identification number, which was used for extraction, but for anonymization these were replaced by an ID number allowing identification of measurements for the same person while disallowing personal referral. The extraction included analyses results of FVL and the aPC ratio in an anonymised form, along with age and gender. Data were categorized in three groups based on the FVL gene test: Wildtype (no Arg506Gln mutation), heterozygous (one Arg506Gln allele mutation) or homozygous (two Arg506Gln allele mutations). As no data were referable to specific individuals, permissions from the Danish authorities were not required, and according to Danish law, studies based solely on register data do not require approval from an Ethics Review Board [7] .
Blood sampling
Blood was drawn from an antecubital vein into 3.2% (109 mM) trisodium citrate BD vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ, USA), and within 30 min the sample was centrifuged for 15 min at 2000 g. Finally, plasma was isolated and stored at −80 °C until analysis. For DNA testing, genomic DNA was isolated from peripheral leukocytes by ammonium acetate precipitation.
Arg506Gln DNA test
A 20 μL sample was amplified in a GeneAmp PCR System 9600 (PerkinElmer, Luxembourg) with dedicated reagents and primers as previously described [8] . The quality of this analysis was assured by adherence to the external quality control program from Referenzinstitut für Bioanalytik (Ringversuche, Bonn, Germany).
Activated protein C ratio analysis
Plasma was incubated for 4 min at 37 °C with an activated partial thromboplastin time (aPTT) reagent. Afterwards, CaCl 2 or aPC + CaCl 2 was added to initiate the coagulation process, and time to clot formation was registered with aPC both present and absent, respectively. This process was performed using the Coatest APC™ Resistance (Chromogenix, Instrumentation Laboratory, Bedford, MA, USA). Afterwards, the aPC ratio was calculated using the formula: aPC ratio = aPTT (seconds) [aPC + CaCl 2 ]/aPTT (seconds) [CaCl 2 ]. The result was then divided with a normal plasma pool reference. The manufacturer (Chromogenix, Instrumentation Laboratory, Bedford, MA, USA) provides a normal reference for the aPC resistance test of 2.0-5.0, but unfortunately no cut-off for pathological values. The quality of this analysis was assured by adherence to the external quality control program from the UK National External Quality Assessment (UK-NEQAS).
Sensitivity, specificity, positive and negative predictive values
Sensitivity, specificity, positive and negative predictive values were calculated for all the aPC ratios by the following formulas:
Sensitivity (=true positive rate) defined as the number of FVL positive individuals with an aPC ratio below a fixed cut-off level, divided by the total number of FVL positive individuals.
Specificity (=true negative rate) defined as the number of FVL negative individuals with an aPC ratio above a fixed cut-off level, divided by the total number of FVL negative individuals.
Positive predictive value (PPV) defined as the number of FVL positive individuals with an aPC ratio below a fixed cut-off level, divided by the total number of individuals with an aPC ratio below the fixed cut-off level Negative predictive value (NPV) defined as the number of FVL negative individuals with an aPC ratio above a fixed cut-off level, divided by the total number of individuals with an aPC ratio above the fixed cut-off level.
Additionally, receiver operating characteristics (ROC) curves were constructed and area under the curve (AUC) was calculated using the trapezoidal rule.
Statistical analyses
Distribution of data was evaluated for normality by histogram overviews. Correlation analysis was performed using the Pearson product-moment correlation coefficient for normally distributed data and the Spearman's rank correlation coefficient for non-normally distributed data, respectively. Additionally, comparison analysis was performed for FVL negative individuals (wildtype) vs. FVL positive individuals (i.e. FVL heterozygous and homozygous combined). The unpaired Student t test was used for normally distributed data. The chi-square (χ 2 )-test was used for proportion comparison. A p-value <0.05 was considered statistically significant.
Results
In total, 1081 individuals were investigated for FVL mutation status and the aPC ratio was calculated. Baseline data is presented in Table 1 . Of all included individuals, 928 were FVL negative, while 153 were FVL positive. The mean age of included FVL negative individuals was 38 ± 15 years, which differed significantly from the FVL positive individuals (41 ± 15 years) (p = 0.01). Among females, 12% was FVL positive, which differed significantly (p < 0.01) from males of which 19% were FVL positive.
The accumulated aPC ratios are shown in Figure 1 for all FVL positive and negative individuals, respectively. Based on a histogram with a roughly bell-shaped curve, age was judged to be normally distributed with a peak at age 28. The same was true for the aPC ratio with a peak at 2.1 for FVL positive individuals and 2.5 for FVL negative individuals.
The association between the aPC ratio and FVL
Based on the ROC curve and the distribution seen in Figure 1 , the optimal cut-off was 2.4. When applied, it resulted in 94% of FVL positive individuals and 29% of FVL negative individuals with an aPC ratio ≤2.4. However, of all individuals with an aPC ratio ≤2.4, only 35% were FVL positive. Moreover, 99% of all individuals with an aPC ratio >2.4 were FVL negative. The specificity, sensitivity, positive predictive value and negative predictive value are presented for different aPC ratios in Figure 2 . Additionally, the ROC curve is presented in Figure 3 . The AUC was 0.93. 
Gender-related aPC ratio
Mean aPC ratios for females and males are presented in Table 1 , while percentage of females and males with an aPC ratio equal to or below different cut-off values are presented in Table 2 . The mean aPC ratio of FVL negative females was 2.6 ± 0.4, which was significantly lower (p < 0.01) than the mean aPC ratio in males (2.8 ± 0.5). In FVL positive females, the mean aPC ratio was 2.0 ± 0.3, which was also significantly lower than in males with a mean aPC of 2.1 ± 0.3 (p < 0.05). Of FVL negative females, 35% had an aPC ratio ≤2.4. This differed statistically from males (p < 0.01), of which only 18% had an aPC ratio ≤2.4. Of FVL positive females, 97% had an aPC ratio ≤2.4 compared to 91% of the male counterparts (p = 0.11).
Age-related aPC ratio
No significant correlation was found between age and aPC ratio (r = −0.06 in FVL positive individuals and r = 0.17 in FVL negative individuals). There was also no correlation between age and aPC ratio when analyzing males and females separately.
Discussion
To the best of our knowledge, this is one of the largest studies on the association between aPC ratio and FVL [9] [10] [11] [12] , and the first to take gender into consideration. In order to use aPC ratio to identify FVL positive individuals, previous studies have used a cut-off at 2.0 with a sensitivity of 43%-86%, a specificity of 75-98% and a PPV of 97% [10] [11] [12] . With a cut-off at 2.0, our study found similar sensitivity of 44% and specificity of 99%, but a somewhat lower PPV of 86%. Another study with 435 individuals used a cut-off at 1.89 and found a high diagnostic accuracy with 99% sensitivity, 99% specificity, 100% PPV and 97% NPV [9] . With a cut-off at 1.9, we found a 31% sensitivity, 100% specificity, 92% PPV and 90% NPV. Even though specificity, PPV and NPV is comparable to Herskovits et al., we found a considerably lower sensitivity. With only one third of FVL positive individuals having an aPC ratio of 1.9 or less, our study suggests a higher aPC ratio cut-off. When considering the ROC curve (Figure 3) , the optimal cut-off is between 2.3 and 2.4, with a sensitivity of 89-94%, specificity of 71-84%, PPV of 35-48% and NPV of 98-99%. Additionally, with an AUC of 0.93 the ROC curve shows that aPC ratio can sufficiently discriminate FVL positive individuals from FVL negative individuals.
It must be emphasized that the FVL prevalence of 14.2% among the 1081 individuals included in this study is considerably higher than the general prevalence of FVL in Denmark, which is 6.6% [8] . This is due to the fact that the study was conducted on individuals admitted for thrombophilia investigation, and a higher prevalence of FVL mutations is therefore natural in this preselected population. As increasing prevalence will induce increased PPV and decreased NPV, the results must be considered in view of this considerable higher prevalence [13, 14] . However, the purpose was to test if the aPC ratio can be used in the diagnostic process, and with a very high NPV (99%) this indeed seems to be the case.
We found a lower frequency of FVL mutations in women, and the fraction of females with an aPC ratio ≤2.0 and ≤2.4, respectively, was significantly higher than in males. Moreover, the mean aPC ratio was significantly lower in females than in males, both in FVL positive and negative individuals. This could indicate a clinically relevant gender difference and reflect an increased VTE risk in the women investigated. This could be due to increased levels of estrogen (e.g. during pregnancy [15] , use of oral contraceptive (OC) [16] or tamoxifen treatment [17] ), which decreases the aPC ratio (i.e. inducing aPC resistance) [1] . Unfortunately, due to completely anonymization, further information of included individuals was unavailable. Despite this, our results suggest that a gender-specific aPC ratio cut-off could be considered, and perhaps an estrogen-specific history should be obtained before requesting the aPC ratio. However, a decision on this matter warrants confirmatory studies on the correlation between the aPC ratio, sex and estrogen levels [18] .
The turn-around time and cost of the different test approaches are of course important. In general, more time is used to perform DNA testing, depending on which DNA extraction step is used. New promising extraction protocols could turn out to enable faster turn-around times, and also, prices for DNA testing has decreased considerably the last 5−10 years. Still, aPC testing requires merely an aPTT measurement and addition of different substrates (CaCl 2 , aPC, etc.), none of which are that expensive. As neither of the approaches seems possible to automate, it will still be a laborious process and altogether, the optimal approach would probably be to minimize the number of thrombophilia testing as recommended lately [19] . Modified aPTT assays, using pre-dilution with FV deficient plasma, has shown 100% sensitivity and specificity for FVL mutation [20, 21] . However, the modified assays, is specific to FVL mutation, but does not provide information on overall coagulation competence, as the original aPTT assay does [21] . In this study, patients where referred for general thrombophilia testing, and therefore the original aPTT assay was used to test any origin of aPC resistance, along with a FVL mutation test. Moreover, a normalized aPC ratio was used to reduce potential assay variability.
This study has some limitations that must be addressed. It was a retrospective case-control study and therefore has increased risk of selection and information biases. Due to completely anonymization of included individuals, only the results of FVL, the aPC ratio, age and gender were available. The reason for thrombophilia testing, clinical history, potential pseudo-homozygosity, as well as additional information about parameters affecting aPC, e.g. pregnancy or use of oral contraceptives, was not obtainable [22] . Although, a limited spectrum of data increases the risk of biases, this study included a large number of analyses, which to some extent counterbalance this. Our study is based on a cohort with a prevalence of 14.2%, which influenced PPV and NPV. As the purpose was to test if the aPC ratio is accurate at identifying FVL positive individuals, we posit that PPV is more important than NPV, and therefore a study population of 1081 should be sufficient [13] . Twice as many females than males were included in the study, but the FVL prevalence in females was significantly lower than in males, which could be accidental, but it could also reflect that more females in general are investigated for inherited thrombophilia. This study is based on one laboratory technique for testing the aPC ratio and one for FVL. This study was performed on individuals referred for thrombophilia testing, and it therefore warrants further investigations to disclose whether the outcome of this preselected group is applicable to healthy, un-selected individuals.
Despite these limitations, our results indicate that a gender-specific aPC ratio cut-off level could be considered, and aPC ratio could due to its low cost be used as a first line test for FVL, but those found positive must be confirmed with a DNA test.
